A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs Alectinib (Primary) ; Brigatinib (Primary) ; Ceritinib (Primary) ; Crizotinib (Primary) ; Ensartinib (Primary) ; Lorlatinib (Primary) ; Carboplatin; Cisplatin; Pemetrexed
- Indications Carcinoma; Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 10 Sep 2019 Trial design presented at the 20th World Conference on Lung Cancer.
- 12 Apr 2019 Status changed from not yet recruiting to recruiting.
- 25 Jan 2019 Planned initiation date changed from 13 Jan 2019 to 1 Apr 2019.